Rational HIV immunogen design to target specific germline B cell receptors.
Jardine, J., Julien, J.P., Menis, S., Ota, T., Kalyuzhniy, O., McGuire, A., Sok, D., Huang, P.S., MacPherson, S., Jones, M., Nieusma, T., Mathison, J., Baker, D., Ward, A.B., Burton, D.R., Stamatatos, L., Nemazee, D., Wilson, I.A., Schief, W.R.(2013) Science 340: 711-716
- PubMed: 23539181 
- DOI: 10.1126/science.1234150
- Primary Citation of Related Structures:  
4JPI, 4JPJ, 4JPK - PubMed Abstract: 
Vaccine development to induce broadly neutralizing antibodies (bNAbs) against HIV-1 is a global health priority. Potent VRC01-class bNAbs against the CD4 binding site of HIV gp120 have been isolated from HIV-1-infected individuals; however, such bNAbs have not been induced by vaccination ...